PMC:7408073 / 76971-77206 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T444","span":{"begin":168,"end":175},"obj":"Body_part"}],"attributes":[{"id":"A444","pred":"fma_id","subj":"T444","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"The surprising aspect is that circulating (differently from membrane bound) ACE2 is expected to protect from viral infection and clinical trials using recombinant ACE2 protein are being pursued (ClinicalTrials.gov number, NCT04287686)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"2734","span":{"begin":76,"end":80},"obj":"Gene"},{"id":"2735","span":{"begin":163,"end":167},"obj":"Gene"},{"id":"2784","span":{"begin":109,"end":124},"obj":"Disease"}],"attributes":[{"id":"A2734","pred":"tao:has_database_id","subj":"2734","obj":"Gene:59272"},{"id":"A2735","pred":"tao:has_database_id","subj":"2735","obj":"Gene:59272"},{"id":"A2784","pred":"tao:has_database_id","subj":"2784","obj":"MESH:D001102"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The surprising aspect is that circulating (differently from membrane bound) ACE2 is expected to protect from viral infection and clinical trials using recombinant ACE2 protein are being pursued (ClinicalTrials.gov number, NCT04287686)."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T390","span":{"begin":109,"end":124},"obj":"Disease"},{"id":"T391","span":{"begin":115,"end":124},"obj":"Disease"}],"attributes":[{"id":"A390","pred":"mondo_id","subj":"T390","obj":"http://purl.obolibrary.org/obo/MONDO_0005108"},{"id":"A391","pred":"mondo_id","subj":"T391","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"The surprising aspect is that circulating (differently from membrane bound) ACE2 is expected to protect from viral infection and clinical trials using recombinant ACE2 protein are being pursued (ClinicalTrials.gov number, NCT04287686)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T932","span":{"begin":60,"end":68},"obj":"http://purl.obolibrary.org/obo/UBERON_0000158"}],"text":"The surprising aspect is that circulating (differently from membrane bound) ACE2 is expected to protect from viral infection and clinical trials using recombinant ACE2 protein are being pursued (ClinicalTrials.gov number, NCT04287686)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T81193","span":{"begin":168,"end":175},"obj":"Chemical"}],"attributes":[{"id":"A96620","pred":"chebi_id","subj":"T81193","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"The surprising aspect is that circulating (differently from membrane bound) ACE2 is expected to protect from viral infection and clinical trials using recombinant ACE2 protein are being pursued (ClinicalTrials.gov number, NCT04287686)."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T142","span":{"begin":109,"end":124},"obj":"http://purl.obolibrary.org/obo/GO_0016032"}],"text":"The surprising aspect is that circulating (differently from membrane bound) ACE2 is expected to protect from viral infection and clinical trials using recombinant ACE2 protein are being pursued (ClinicalTrials.gov number, NCT04287686)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T378","span":{"begin":0,"end":235},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The surprising aspect is that circulating (differently from membrane bound) ACE2 is expected to protect from viral infection and clinical trials using recombinant ACE2 protein are being pursued (ClinicalTrials.gov number, NCT04287686)."}